Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $334.3 million.

  • AtriCure's Non-Current Assets fell 331.13% to $334.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 221.91%. This contributed to the annual value of $341.5 million for FY2024, which is 177.86% down from last year.
  • AtriCure's Non-Current Assets amounted to $334.3 million in Q3 2025, which was down 331.13% from $337.6 million recorded in Q2 2025.
  • In the past 5 years, AtriCure's Non-Current Assets ranged from a high of $419.2 million in Q4 2021 and a low of $1.5 million during Q2 2021
  • Moreover, its 5-year median value for Non-Current Assets was $346.4 million (2024), whereas its average is $322.8 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 1728.53% in 2021, then skyrocketed by 2543402.55% in 2022.
  • AtriCure's Non-Current Assets (Quarter) stood at $419.2 million in 2021, then fell by 11.69% to $370.2 million in 2022, then decreased by 6.09% to $347.7 million in 2023, then dropped by 1.78% to $341.5 million in 2024, then decreased by 2.1% to $334.3 million in 2025.
  • Its Non-Current Assets was $334.3 million in Q3 2025, compared to $337.6 million in Q2 2025 and $340.1 million in Q1 2025.